Mesa Laboratories Q3 revenue rises 3.6%

Mesa Laboratories

03/02/2026 13:07

Overview

Life science tools maker's fiscal Q3 revenue rose 3.6% yr/yr

Operating income for fiscal Q3 increased 38%

Company repaid $8.7 mln of debt, reducing leverage ratio to 2.62

Outlook

Mesa expects positive momentum to continue in 4Q26

Company anticipates slight moderation in profitability margins over next quarters

Mesa expects CG division to return to positive organic growth in 4Q26

Result Drivers

BIOPHARMACEUTICAL DEVELOPMENT - Strong growth driven by higher sales of Immunoassays and Peptides instruments

STERILIZATION AND DISINFECTION CONTROL - Growth due to higher sales volumes and modest price increases

CLINICAL GENOMICS CHALLENGES - Revenue contraction in China due to regulatory and tariff headwinds

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
$0.65
Q3 Net Income
$3.63 mln
Q3 Basic EPS
$0.66
Q3 Gross Profit
$41.80 mln
Q3 Operating Expenses
$33.82 mln
Q3 Operating Income
$7.98 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Mesa Laboratories Inc is $99.00, about 23% above its February 2 closing price of $80.50

The stock recently traded at 49 times the next 12-month earnings vs. a P/E of 44 three months ago

Press Release: ID:nGNX4gZPqx

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)